Disease-induced alterations in plasma drug-binding proteins and their influence on drug binding percentages in dogs

Veterinary Quarterly

Volumn 22, Issue 1, 2000, Pages 43-49

  Ikenoue, N ^a   Saitsu, Y ^a   Shimoda, M ^a   Kokue, E ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Albumin; Alpha1 acid glycoprotein; Dogs; Drug interaction; Protein binding

Indexed keywords

DRUG; DRUG BINDING PROTEIN;

ANIMAL DISEASE; ARTICLE; DOG; DRUG BINDING; DRUG PROTEIN BINDING; NONHUMAN; PROTEIN BLOOD LEVEL;

ALBUMINS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOGS; DRUG INTERACTIONS; FEMALE; MALE; NAPROXEN; OROSOMUCOID; PROTEIN BINDING; VETERINARY DRUGS;

ANIMALIA; CANIS FAMILIARIS;

EID: 0033980638     PISSN: 01652176     EISSN: 18755941     Source Type: Journal    
DOI: 10.1080/01652176.2000.9695022     Document Type: Article

References (35)

1. Abramson FP. Dose-response behavior of the induction of a 1-acid glycoprotein by phenobarbital in the dog. Drug Metabolism and Disposition 1988; 16: 546–50.
2. Belpaire FM, DeRick A, Dello C, Fraeyman N, and Bogaert MG. a 1-acid glycoprotein and serum binding of drugs in healthy and diseased dogs. Journal of Veterinary Pharmacology and Therapeutics 1987; 10: 43–8.
3. Benet LZ, and Williams RL. Design and optimization of dosage regimens; pharmacokinetic data. In: Hardman JO, Limbird LE, Molinoff PB, Ruddon RW, and Gilman AG, editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996: 1650–1735.
4. Condner EC, and Maslin WR. Investigation of renal protein loss in dogs with acute experimentally induced Ehrlichia canis infection. Am J Vet Res 1992; 53 (3): 294–9.
5. Conner JG, and Eckersall PD. Acute phase responsein the dog following surgical trauma. Research in Veterinary Science 1988; 45: 107–10.
6. Dello CP, Belpaire FM, DeRick, A, and Fraeyman NH. Influence of inflammation on serum concentration, molecular heterogeneity and drug binding properties of canine alpha-1-acid glycoprotein. Journal of Veterinary Pharmacology and Therapeutics 1988; 11: 71–6.
7. Doumas BT, Watson WA, and Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clinica Chimica Acta 1971; 31: 87–96.
8. Edwards DJ, Lalka D, Cerra F, and Slaughter RL. Alpha Lacid glycoprotein concentration and protein binding in trauma. Clinical Pharmacology and Therapeutics 1982; 31: 62–7.
9. Fishman WH, and Charlap, S. The alpha- and beta-adrenergic blocking drugs. In: Parmley WW, and Chatterjee K, editors. Cardiovascular pharmacology. Hong Kong: Wolfe; 1994: 5.2–20.
10. Fox SM, and Johnston, S.A. Use of carprofen for the treatment of pain and inflammation in dogs. Journal of American Veterinary Medical Association 1997; 210 (10): 1493–98.
11. Frey HH, and Rieh B. Pharmacokinetics of naproxen in the dog. Am J Vet Res 1981; 42 (9): 1615–7.
12. Gilmour MA, and Walshaw R. Naproxen-induced toxicosis in dog. J Am Vet Med Assoc 1987; 191 (11): 1431–32.
13. Hvidberg EF, and Dam M. Clinical pharmacokinetics of anticonvulsants. Clinical Pharmacokinetics 1976; 1 (3): 161–88.
14. Kinoshita T, Son D-S, Shimoda M, and Kokue E. Impact of age-related alteration of plasma alpha Lacid glycoprotein concentration on erythromycin pharmacokinetics in pigs. Am J Vet Res 1995; 56: 362–5.
15. Kremer JMH, Wilting J, and Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacological Reviews 1988; 40:1–47.
16. McKellar QA, Delatour P, and Lees P. Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. Journal of Veterinary Pharmacology and Therapeutics 1994; 17 (6): 447–54.
17. McKellar QA, Galbraith EA, Bogan JA, Russell CS, Hooke RE, and Lees P. Flunixin pharmacokinetics and serum thromboxane inhibition in the dog. Vet Rec 1989; 124: 651–4.
18. Neff-Davis CA. Therapeutic drug monitoring in the veterinary clinics. In: Papich, M.G., editor. Clinical pharmacology vol 18 num 6. Philadelphia: W.B. Saunders Company; 1988: 161–79.
19. Nielsen UCK, Ostergard EH, Frey HH. Versuche zur dosierung von Phenylbutazon beim Hund. D.T.W., 1969; 76: 371–87.
20. Nilsen OG, and Jacobsen S. The influence of salts and differences in protein isolation procedure on the binding of quinidine to human serum albumin. Biochemical Pharmacology 1976; 25: 1261–6
21. Ogilvie GK, Walters LM, Greeley SG, Henkel SE, and Salman MD. Concentration of al-acid glycoprotein in dogs with malignant neoplasia. J Am Vet Med Assoc 1993; 203 (8): 1144–6.
22. Plaisance KI, Drusano GL, Forrest A, Townsend RJ, and Standiford HC. Pharmacokinetic Evaluation of Two Dosage Regimens of Clindamycin Phosphate. Agents and Chemotherapy 1988; 33 (5): 618–20.
23. Rakhit A, Kunitani M, Holford NH, and Riegelman S, Improved liquid-chromatographic assay of quinidine and its metabolites in biological fluids., Clinical Chemistry 1982; 28 (7):1505–9.
24. Rick A de, Belpaire F, Bogaert M, and Rosseel MT. Influence of enhanced serum protein binding on the pharmacokinetics and the antiarrhythmic effect of lidocaine in the dog. European Association of Veterinary Pharmacology and Toxicology, 3rd Congress 1985: 113.
25. Rikihisa Y, Yamamoto S, Kwak I, lqbal Z, Kociba G, Mott J. and Chichanasiriwithaya, W. C-reactive protein and al-acid glycoprotein levels in dogs infected with Ehrlichia canis. Journal of Clin Microbiol 1994; 32 (4): 912–7.
26. Roudebush P, and Morse GE. Naproxen toxicosis in dog. J Am Vet Med Assoc 1981; 179 (8): 805–6.
27. Shimoda M, Kokue E, Hayama T, and Vree TB. Effect of albumin distribution-A simulation analysis of the effect of altered albumin distribution on the apparent volume of distribution and apparent elimination rate constant of drugs. Pharmaceutisch Weekblad. Scientific Edition 1989; 11: 87–91.
28. Sugiyama Y. Protein binding examinations. In: Hanano M, Umemura K, Iga T, editors. Applied pharmacokinetics - theory and experiments - Tokyo: SOFT SCIENCE; 1985: 337–80.
29. Tagawa Y, Kokue E, Shimoda M, and Son D-S. alphal-acid glycoprotein-binding as a factor in age-related changes in the pharmacokinetics of trimethoprim in piglets. Vet Quart 1994; 16: 13–7.
30. Vree TB, Shimoda M, Driessen JJ, Guelen PJM, Janssen TJ, Termond EFS, Dalen R van, Hafkenscheid CM, and Dirksen MSC. Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients. Clinical Pharmacology and Therapeutics 1989; 46 (5): 537–44.
31. Yacobi A, and Levy G. Comparative pharmacokinetics of coumarin anticoagulants XIV: relationship between protein binding, distribution, and elimination kinetics of warfarin in rats. Journal of Pharmaceutical Sciences 1975; 64 (10): 1660–4.
32. Yacobi A, and Levy G. Effect of serum protein binding on sulfisoxazole distribution, metabolism, and excretion in rats. Journal of Pharmaceutical Sciences 1979; 68 (6): 742–6.
33. Zeineh RA, Barrett B, Niemirowski L, and Fiorella BJ. Turnover rate of orosomucoid in the dog with sterile abscess. American Journal of Physiology 1972; 222 (5): 1326–32.
34. Zini R, Riant P, Barre R, and Tillement JP. Disease-induced variations in plasma protein levels. Implication for drug dosage regimens (Part I). Clinical Pharmacokinetics 1990; 19 (2): 145–59.
35. Zini R, Riant P, Barre R, and Tillement JP. Disease-induced variations in plasma protein levels. Implication for drug dosage regimens (Part II). Clinical Pharmacokinetics 1990; 19 (3): 218–29.